May 22nd 2024
Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma.
May 21st 2024
Inavolisib/palbociclib/fulvestrant was granted FDA granted breakthrough therapy designation for PIK3CA-mutated, HR-positive/HER2-negative breast cancer.
May 17th 2024
TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.
PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.
May 16th 2024
Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.
May 14th 2024
CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Repotrectinib has been approved by China’s National Medical Products Administration for the treatment of patients with ROS1-positive NSCLC.
Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.
May 9th 2024
The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.
Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.
May 8th 2024
Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.
May 7th 2024
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
May 6th 2024
The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
May 3rd 2024
Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.
A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.
May 2nd 2024
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.
May 1st 2024
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.